Fly News Breaks for February 21, 2020
Feb 21, 2020 | 12:22 EDT
Wedbush analyst Liana Moussatos raised her price target on BioMarin to $175 from $158 and maintained an Outperform rating.
News For BMRN From the Last 2 Days
Mar 3, 2021 | 08:33 EST
BioMarin Pharmaceutical announced that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide for children with achondroplasia, the most common form of disproportionate short stature in humans. The 52-week study consists of approximately 70 infants and young children with achondroplasia, aged zero to less than five years old. The study will be followed by a subsequent open-label extension trial where all children receive active treatment. Children in this study will have completed a minimum three- or six-month baseline study to determine their respective baseline growth prior to entering the Phase 2 study. The objectives of the study are to evaluate safety, tolerability, and the effect of vosoritide on growth. The company also plans to augment the height data with assessments including proportionality, functionality, quality of life, sleep apnea, and foramen magnum dimension, as well as the advent of major illnesses and surgeries.